Navigation Links
Dr. Charles Sanders to Become Lead Director of Epiphany Biosciences
Date:10/2/2008

SAN FRANCISCO, Oct. 2 /PRNewswire-FirstCall/ -- Epiphany Biosciences, Inc. announced today that Dr. Charles Sanders has accepted the position of Lead Director. Dr. Sanders is a highly experienced biotechnology and pharmaceutical executive, currently serving as Lead Director of Genentech. He has also served as chief executive officer of Glaxo Inc., from 1989-1994 and chairman of the board from 1992-1995. In addition, Dr. Sanders is also a member of the Boards of Directors of Vertex Pharmaceuticals, Cephalon, Inc., and Icagen, Inc.

"The Epiphany strategy of addressing long-term disease as sequelae of chronic viral infection offers a unique perspective in addressing unmet medical needs in a variety of patients. Dr. Volinsky has assembled an outstanding team and I am happy to work with them to reach their goals," reported Dr. Sanders.

"We are elated to have Dr. Sanders as our Lead Director. His extensive experience in the biotechnology industry has already helped propel Epiphany forward and we look forward to his continued input and counsel," stated Fred Volinsky, MD, the Chief Executive Officer of Epiphany Biosciences.

"Next year will be a critically important time for the company as we plan to collect data from up to four Phase 2 studies as well as continue further development of our HCV pipeline," commented Brian Murphy, MD, Chief Medical Officer of Epiphany. "Dr. Sanders' guidance will be very valuable at this pivotal time."

About Epiphany Biosciences:

Epiphany Biosciences is a privately-held company developing therapeutic products and diagnostic technologies that treat or help prevent the spread of pathogenic viruses, including varicella virus (VZV), Epstein-Barr Virus (EBV) and hepatitis C virus (HCV).

Contact:

Fred Volinsky

CEO of Epiphany Biosciences, Inc.

+1-415-765-7193


'/>"/>
SOURCE Epiphany Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Charles C. Harwood, Jr., Joins Cellectar, Inc.s Board of Directors
2. Ocular Biopharmaceutical Company Charlesson Announces $1.6MM in New Funding and Upcoming Presentations at The Association for Research in Vision and Ophthalmology
3. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
4. Dr. Charles A. Sims of California Cryobanks Family Cord Blood Services Named to National Stem Cell Advisory Council
5. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
6. Informed Medical Communications Appoints Charles T. Saldarini to Board of Directors
7. Leading Lobbying Firm Celebrates Growth and New Name: Troutman Sanders Strategies
8. Squire Sanders Stands Out in Independent Analysis of Law Firms in Europe
9. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
10. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
11. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):